Genelux Corporation stock is down -9.66% since 30 days ago. The next earnings date is Dec 19, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.